NOX Stock Overview
A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Noxopharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.10 |
| 52 Week High | AU$0.15 |
| 52 Week Low | AU$0.051 |
| Beta | 0.69 |
| 11 Month Change | -20.00% |
| 3 Month Change | -9.09% |
| 1 Year Change | -13.04% |
| 33 Year Change | -77.27% |
| 5 Year Change | -69.23% |
| Change since IPO | -45.95% |
Recent News & Updates
Recent updates
Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation
Aug 24
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Jan 04We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate
Jul 22Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Feb 27We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth
Nov 10Is Noxopharm (ASX:NOX) Using Debt Sensibly?
Jun 04Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 17These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively
Sep 04Shareholder Returns
| NOX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -4.8% | -3.6% | 1.5% |
| 1Y | -13.0% | 10.0% | 17.2% |
Return vs Industry: NOX underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: NOX underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| NOX volatility | |
|---|---|
| NOX Average Weekly Movement | 18.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: NOX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: NOX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Gisela Mautner | www.noxopharm.com |
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types.
Noxopharm Limited Fundamentals Summary
| NOX fundamental statistics | |
|---|---|
| Market cap | AU$30.68m |
| Earnings (TTM) | -AU$3.58m |
| Revenue (TTM) | AU$2.40m |
12.2x
P/S Ratio-8.2x
P/E RatioIs NOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOX income statement (TTM) | |
|---|---|
| Revenue | AU$2.40m |
| Cost of Revenue | AU$2.94m |
| Gross Profit | -AU$534.81k |
| Other Expenses | AU$3.04m |
| Earnings | -AU$3.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | -22.28% |
| Net Profit Margin | -149.07% |
| Debt/Equity Ratio | 0% |
How did NOX perform over the long term?
See historical performance and comparison